Too many patients and families continue to experience the effects of serious health conditions that have no available treatments or cures.
AMAG seeks to collaborate on and acquire promising therapies at various stages of development, and advance them through the clinical and regulatory process to deliver new treatment options to patients.
Digoxin Immune Fab (DIF)
As part of our commitment to advance the body of clinical research in maternal health, we have made a significant investment in the late-stage development program of an investigational therapy—digoxin immune fab (DIF)—for the treatment of severe preeclampsia. This potentially life-threatening condition is a contributing factor in a significant number of preterm births in the U.S., yet no approved treatment options currently exist.1